In conclusion, our study first demonstrated that FOSL1/CIB2/ZEB1 pathway functioned in regulation of gefitinib resistance and CIB2 could be applied as a novel biomarker for diagnosis of drug resistance of lung cancer. Here, ZEB1 is linked to lung carcinoma.